During February 2026, governments and regulators across Canada, the United States, and Europe advanced regulatory and governance measures directly affecting AI in healthcare. Key themes included quality system harmonisation, acceleration pathways for digital health devices, medical device regulatory amendments, and the evolution of national AI governance strategies with healthcare as a priority sector.
For founders, compliance leaders, and healthcare AI vendors, February 2026 signals continued tightening of lifecycle oversight, increasing alignment with international standards, and growing emphasis on post-market accountability.
Canada
1) Consultation Report – Next Chapter of Canada’s AI Leadership (February 5, 2026)
The Government of Canada, through Innovation, Science and Economic Development Canada, released a formal consultation report outlining stakeholder feedback on the next phase of Canada’s artificial intelligence strategy. The report reflects engagement with industry participants, academic institutions, civil society groups, and sector-specific actors. Among all sectors discussed, healthcare emerged as a priority area requiring structured and carefully calibrated governance.
The consultation highlights three recurring themes: the importance of risk-based governance, the need for greater regulatory clarity for high-impact AI systems, and the desirability of harmonisation with international regulatory frameworks. The emphasis on risk-based governance suggests movement toward a tiered regulatory model in which obligations correspond to the potential impact of AI systems. In healthcare, where tools may influence diagnosis, treatment decisions, or patient risk prediction, the perceived risk profile is inherently higher than in many other sectors.
Although the consultation report itself does not create binding legal obligations, it serves as a directional signal. It indicates that future federal measures may formalise expectations concerning risk classification, documentation, transparency, and accountability for AI-enabled clinical tools. Organisations developing or deploying AI in healthcare may therefore anticipate more structured governance requirements, particularly for systems that could materially affect patient outcomes.
The consultation signals that future federal AI policy development will likely move toward structured governance models rather than voluntary principles alone. The emphasis on “risk-based governance” suggests tiered obligations depending on system impact, particularly in safety-critical domains like healthcare. The reference to harmonisation indicates awareness of parallel developments internationally, especially in medical device governance and AI regulatory frameworks.
Next Chapter of Canada’s AI Leadership – Consultation
How it applies to AI in Healthcare:
Healthcare AI systems are typically considered high-impact due to patient safety implications. The consultation signals that organisations deploying or developing AI tools in healthcare may anticipate more formalised obligations concerning:
- Risk assessment
- Documentation and traceability
- Governance controls
- Transparency regarding system performance and limitations
Although the consultation itself is not binding law, it functions as a directional indicator for future regulatory measures.
United States
1) TEMPO Pilot Program for Digital Health Devices (February 3, 2026)
The U.S. Food and Drug Administration introduced the Technology-Enabled Meaningful Patient Outcomes (TEMPO) Pilot Program through its Digital Health Center of Excellence. The initiative is designed to accelerate access to certain digital health and AI-enabled devices while preserving regulatory safeguards and strengthening post-market oversight mechanisms.
The program reflects the FDA’s continuing effort to adapt regulatory oversight to emerging digital and AI technologies without weakening patient safety standards. By focusing on “meaningful patient outcomes,” the initiative underscores the importance of demonstrable clinical benefit and real-world effectiveness rather than purely technical performance.
For developers of AI-driven Software as a Medical Device, the TEMPO program suggests a clearer but more structured pathway to market. While access may be streamlined in certain respects, expectations surrounding clinical validation, evidence generation, and real-world performance monitoring are reinforced. The reference to alignment with reimbursement frameworks indicates that evidentiary standards may increasingly consider not only regulatory approval but also practical demonstration of value in healthcare settings. This reinforces the importance of lifecycle evidence generation rather than one-time pre-market validation.
FDA Digital Health Center of Excellence – TEMPO Pilot
How it applies to AI in Healthcare:
AI-driven Software as a Medical Device (SaMD) developers may experience:
- More defined regulatory pathways to market
- Structured expectations regarding:
- Clinical validation
- Evidence generation
- Real-world performance monitoring
- Integration of post-market data into regulatory evaluation
The reference to alignment with reimbursement frameworks suggests that evidence standards may increasingly consider payer expectations and real-world effectiveness, not just pre-market technical validation.
Developers may expect reinforced obligations concerning:
- Clinical performance data
- Ongoing monitoring after deployment
- Transparency around model performance in practice
2) Quality Management System Regulation (QMSR) Alignment with ISO 13485:2016 (Effective February 2, 2026)
The FDA’s amended Quality Management System Regulation became effective in early February 2026 and formally aligns U.S. device quality system requirements with ISO 13485:2016, issued by the International Organization for Standardization. This alignment represents a significant harmonisation milestone between U.S. regulatory requirements and internationally recognised medical device quality standards.
ISO 13485:2016 establishes comprehensive requirements governing the design, development, production, and post-market oversight of medical devices. With the QMSR amendments now effective, U.S. manufacturers must ensure that their quality systems reflect these structured lifecycle controls.
For AI-enabled medical devices, the implications are substantial. Design validation processes must be robust and well documented. Software change management procedures must be clearly defined and traceable. Risk management must be systematic and integrated throughout the product lifecycle. Post-market surveillance must not be treated as an afterthought but as an embedded quality function.
Continuous-learning or adaptive AI systems face particular scrutiny under such a framework. Any update that could alter system performance requires disciplined change control, documentation, and validation processes. The harmonisation with ISO 13485:2016 strengthens expectations that AI medical software be governed with the same rigour traditionally applied to physical medical devices.
Significance of ISO 13485:2016 Alignment
ISO 13485:2016 establishes requirements for:
- Design controls
- Risk management
- Documentation
- Corrective and preventive actions (CAPA)
- Supplier management
- Post-market surveillance
- Lifecycle quality controls
With QMSR alignment, these principles are now embedded directly into U.S. regulatory requirements for medical device manufacturers.
FDA Quality System Regulation / QMSR
How it applies to AI in Healthcare:
AI-enabled medical device manufacturers must ensure lifecycle controls—design validation, software change management, risk management, and post-market surveillance—are aligned with ISO 13485 principles. Continuous-learning AI systems will face heightened scrutiny around change control and documentation.
European Union & United Kingdom
1) Proposed Amendments to EU Medical Devices Regulations (Notified February 2026)
In February 2026, a proposed regulation amending the existing EU Medical Devices Regulation (MDR) and In Vitro Diagnostic Regulation (IVDR) was formally notified for scrutiny procedures. The proposal aims to reduce administrative burdens and refine oversight mechanisms affecting manufacturers across the European Union.
The MDR and IVDR frameworks establish comprehensive requirements for conformity assessments, clinical evaluation, post-market surveillance, and notified body oversight. The proposed amendments, as described, focus on procedural and administrative refinements rather than a wholesale restructuring of the regulatory regime.
For manufacturers of AI-based diagnostic software and clinical decision support systems operating under these frameworks, procedural adjustments may affect conformity assessment timelines, interactions with notified bodies, and transitional compliance arrangements. Because certification processes under MDR and IVDR directly influence market access, even administrative refinements can have operational consequences. Organisations active in the EU market should therefore monitor these developments closely to assess potential impacts on certification pathways and compliance planning.
Proposed Replacement EU Act – MDR/IVDR Amendments
How it applies to AI in Healthcare:
Manufacturers of AI-based diagnostic and clinical decision support software operating under MDR/IVDR frameworks should monitor potential procedural adjustments affecting conformity assessments, notified body capacity, and transitional compliance timelines.
Cross-Cutting Themes
Across Canada, the United States, the European Union, and the United Kingdom, several consistent patterns emerge:
Lifecycle Accountability Is Tightening
Regulators are strengthening expectations regarding:
- Design validation
- Change control
- Post-market monitoring
- Real-world evidence generation
- Quality management system integration
AI systems, particularly in healthcare, are being treated as lifecycle-regulated technologies rather than static software products.
International Harmonisation Is Accelerating
Examples include:
- U.S. alignment of QMSR with ISO 13485:2016
- Ongoing MDR/IVDR procedural refinement in the EU
- Canadian emphasis on harmonisation with international AI frameworks
This reflects convergence in global medical device governance affecting AI technologies.
Healthcare Is Recognised as a High-Risk, High-Impact AI Sector
National AI strategy discussions consistently identify healthcare as:
- Safety-critical
- Public-trust-sensitive
- Requiring structured oversight
This sector-specific prioritisation suggests that AI in healthcare will face stricter and more formalised governance than lower-risk AI domains.
Key Considerations for Regulatory Alignment
1) Quality Management Systems
Organisations may review QMS structures to ensure alignment with ISO 13485:2016 principles, especially regarding:
- AI software validation
- Design controls
- Risk management
- Change documentation
2) Post-Market Monitoring
Developers may assess capabilities for:
- Real-world performance tracking
- Adverse event reporting
- Safety monitoring
- Version control documentation
3) EU Regulatory Tracking
Manufacturers operating under MDR/IVDR frameworks may:
- Monitor amendment proposals
- Evaluate conformity assessment implications
- Assess potential changes to notified body processes
4) Participation in National AI Consultations
Engagement in consultations (e.g., Canadian AI strategy discussions or UK advisory processes) allows:
- Early visibility into regulatory direction
- Opportunity to shape sector-specific governance measures
- Preparation for upcoming compliance obligations
Disclaimer: This checklist is provided for general informational purposes only and does not constitute legal, regulatory, or professional advice; organizations should consult with their legal and compliance departments to ensure adherence to specific jurisdictional requirements.
Sources
- Next Chapter of Canada’s AI Leadership – Consultation (February 5, 2026)https://ised-isde.canada.ca/site/ised/en/public-consultations/next-chapter-canadas-ai-leadership
- FDA Digital Health Center of Excellence – TEMPO Pilot (February 3, 2026)https://www.fda.gov/medical-devices/digital-health-center-excellence
- FDA Quality System Regulation / QMSR (Effective February 2, 2026)https://www.fda.gov/medical-devices/postmarket-requirements-devices/quality-system-qs-regulationmedical-device-good-manufacturing-practices
- Proposed Replacement EU Act – MDR/IVDR Amendments (February 2026)https://www.niassembly.gov.uk/assembly-business/committees/2022-2027/windsor-framework-democratic-scrutiny-committee/eu-acts/proposed-replacement-eu-acts/com20251023/
